Cargando…
How Many Diseases Are Colorectal Cancer?
The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differ...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444041/ https://www.ncbi.nlm.nih.gov/pubmed/22991509 http://dx.doi.org/10.1155/2012/564741 |
_version_ | 1782243618734473216 |
---|---|
author | Greystoke, A. Mullamitha, S. A. |
author_facet | Greystoke, A. Mullamitha, S. A. |
author_sort | Greystoke, A. |
collection | PubMed |
description | The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.” |
format | Online Article Text |
id | pubmed-3444041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34440412012-09-18 How Many Diseases Are Colorectal Cancer? Greystoke, A. Mullamitha, S. A. Gastroenterol Res Pract Review Article The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.” Hindawi Publishing Corporation 2012 2012-09-09 /pmc/articles/PMC3444041/ /pubmed/22991509 http://dx.doi.org/10.1155/2012/564741 Text en Copyright © 2012 A. Greystoke and S. A. Mullamitha. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Greystoke, A. Mullamitha, S. A. How Many Diseases Are Colorectal Cancer? |
title | How Many Diseases Are Colorectal Cancer? |
title_full | How Many Diseases Are Colorectal Cancer? |
title_fullStr | How Many Diseases Are Colorectal Cancer? |
title_full_unstemmed | How Many Diseases Are Colorectal Cancer? |
title_short | How Many Diseases Are Colorectal Cancer? |
title_sort | how many diseases are colorectal cancer? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444041/ https://www.ncbi.nlm.nih.gov/pubmed/22991509 http://dx.doi.org/10.1155/2012/564741 |
work_keys_str_mv | AT greystokea howmanydiseasesarecolorectalcancer AT mullamithasa howmanydiseasesarecolorectalcancer |